Executive Overview
The transition into motherhood is widely acknowledged as one of the most profound psychological and physical transformations a person can experience. Yet, despite the cultural ubiquity of this milestone, the reality of navigating new parenthood often catches first-time mothers off guard. From grappling with a complete restructuring of personal identity to absorbing a crash course in invisible responsibilities—such as infant healthcare decisions—the journey is as challenging as it is rewarding.
In a candid conversation on The Motherly Podcast, sponsored by Pfizer, actress Chloe Bridges and board-certified OB-GYN Dr. Charis Chambers pull back the curtain on the raw, unfiltered realities of stepping into motherhood. Spanning topics from the emotional weight of self-sufficiency to the critical importance of proactive neonatal health, the discussion offers an authoritative yet deeply relatable look at modern parenting.
Central to their conversation is a vital public health discussion regarding Respiratory Syncytial Virus (RSV), a highly contagious pathogen that remains the leading cause of hospitalization for infants in the United States. With nearly half of all RSV-related infant hospitalizations occurring within the first three months of life, understanding maternal immunization options has become an essential pillar of contemporary prenatal care.
Detailed Chronology: The Evolution of First-Time Motherhood
The path to motherhood is rarely linear. For both Bridges and Dr. Chambers, the journey began long before their respective sons—Beau and Joshua—entered the world, unfolding across distinct phases of anticipation, realization, and adaptation.
The Pregnancies and the Mental Shifts
For Chloe Bridges, known for her extensive career in film and television and her education at Columbia University, welcoming her first child with husband Adam Devine in February 2024 marked a total shift in perspective. Before pregnancy, personal health was managed independently. Upon conceiving, however, Bridges experienced an immediate pivot: health was no longer an individual metric, but a shared responsibility intertwined with the well-being of her developing baby.
Simultaneously, Dr. Charis Chambers—a prominent pediatric and adolescent gynecologist, Chief Medical Officer at the cycle-tracking app Clue, and author—found herself on the unfamiliar side of the stethoscope. Despite her extensive medical background, navigating high-risk pregnancy complications, such as monitoring a shortened cervix, forced her to step out of the clinician’s chair and assume the vulnerable position of the patient. Balancing professional expertise with personal medical decisions tested her reliance on trusted healthcare teams.
The Postpartum Awakening and Building a Village
Both women noted that the immediate postpartum period brought an instantaneous rewriting of their daily lives. Dr. Chambers described the surreal moment of holding her newborn while realizing that her established routines, to-do lists, and worldview had dissolved.
A central theme of their chronology is the difficult unlearning of hyper-independence. Both high-achieving professionals had to actively cultivate a support network, learning that accepting help is not an admission of failure, but a fundamental requirement of modern parenting. Whether delegating nursery setup to sisters or requesting uninterrupted sleep from mothers-in-law, both mothers emphasized that the old adage "it takes a village" is a practical survival strategy.
Supporting Context & Metrics: Understanding the Threat of Infant RSV
While the emotional adjustments of motherhood occupy much of a new parent’s mental bandwidth, navigating invisible biological threats requires equal prioritization. Among these, Respiratory Syncytial Virus (RSV) stands out as a critical pediatric concern.
The Scale of RSV in the U.S.
Public health data underscores the severity of RSV among infants:
- Leading Cause of Hospitalization: RSV is the number one cause of hospitalization for babies in the United States.
- Early Vulnerability Window: Nearly 50% of all RSV-related infant hospitalizations occur within the first three months of life.
- Seasonality: The virus typically circulates heavily during the fall and winter months across most of the United States.
Unlike older children and adults—who typically experience mild, cold-like symptoms—infants possess narrow airways and developing immune systems that make them highly susceptible to severe lower respiratory tract disease (LRTD). Symptoms in infants extend beyond standard congestion to include rapid, noisy breathing, chest retractions, and profound exhaustion associated with the increased physical "work of breathing."
Official Perspectives and Medical Insights
During their dialogue, Bridges and Dr. Chambers stressed the importance of filtering out digital noise and relying on verified medical guidance, particularly when evaluating preventative health measures during pregnancy.
Maternal Immunization as a Preventative Strategy
Dr. Chambers emphasized that maternal immunization utilizes the body’s natural physiological processes. Pregnant individuals naturally generate antibodies in response to environmental exposures and pass them passively to the fetus.
To bridge the vulnerability gap during an infant’s first months of life, medical guidelines support maternal vaccination. Dr. Chambers recommended Pfizer’s Respiratory Syncytial Virus Vaccine, ABRYSVO®, which is administered to pregnant individuals at 32 through 36 weeks of gestational age. This targeted window helps protect infants against RSV infection from birth through six months of age during the peak RSV season (September through January in most of the U.S.).
Reflecting on her own experience, Bridges noted:
"RSV wasn’t on my radar. It was something that I learned about from my OBGYN. She recommended I get ABRYSVO for it, and I remain very happy that I listened… and that helped protect him during his first six months of life when he is so vulnerable."
Safety and Considerations
Medical professionals stress that maternal immunization decisions must be weighed carefully with a healthcare provider.
- Gestational Timing: ABRYSVO is administered strictly between 32 and 36 weeks gestational age to avoid potential risks associated with preterm birth.
- Common Side Effects: The most frequent side effects reported in pregnant individuals include injection site pain, headaches, muscle pain, and nausea. Infants may occasionally experience low birth weight and jaundice.
- Contraindications: The vaccine should not be administered to individuals with a history of severe allergic reactions (such as anaphylaxis) to any of its components. Furthermore, surveillance data has noted an increased risk of Guillain-Barré syndrome (severe muscle weakness) following vaccination.
Future Outlook: Redefining Modern Motherhood
As Bridges and Dr. Chambers look toward the future, their aspirations for their sons are rooted in emotional connection, mutual trust, and lifelong support. Bridges hopes her son Beau remembers her not only as a competent and capable parent, but as a playful and joyful companion. Dr. Chambers aims to foster an environment where her son Joshua views her as a trusted advisor whose foundational decisions were anchored in unconditional love before he was even born.
Ultimately, their conversation serves as a roadmap for prospective parents. By destigmatizing the emotional turbulence of identity shifts, advocating for collaborative support networks, and prioritizing proactive medical interventions like RSV immunization, modern mothers are better equipped to protect both their own mental well-being and the health of the next generation.
Important Safety Information & Use
Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.
Reporting Adverse Events:
You are encouraged to report side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791 to help monitor pregnancy outcomes.
What is ABRYSVO?
ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through six months of age.
Please see full Prescribing Information for ABRYSVO at pfi.sr/ABRYSVO_PI.
(C) 2026 Pfizer Inc. All rights reserved. PP-A1G-USA-3233
